The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC.

To better predict these risks, the new guidelines recommend that all stage 2 and 3 colorectal tumors undergo molecular ...

The National Comprehensive Cancer Network ® (NCCN ®) - an alliance of leading cancer centers focusing on maintaining evidence-based expert consensus driven guidelines for care - announces the ...

PLYMOUTH MEETING, PA [March 1, 2021] -- The National Comprehensive Cancer Network® (NCCN®)--an alliance of leading cancer centers--today announced the publication of new NCCN Guidelines® for ...

Today, the National Comprehensive Cancer Network ® (NCCN ®)-a nonprofit responsible for globally utilized guidelines for cancer care-is sharing new NCCN Guidelines Navigator™ resources for breast ...

The NCCN has updated its guidelines on breast, pancreatic, colon, rectal, non-small cell lung, and other cancers. The National Comprehensive Cancer Network (NCCN) has updated its treatment guidelines ...

The MarketWatch News Department was not involved in the creation of this content.-- Nadofaragene firadenovec-vncg received an NCCN Category 2A recommendation for patients with pap ...

NCCN has added ImmunityBio's ANKTIVA to its Clinical Practice Guidelines for BCG-unresponsive non muscle invasive bladder ...

PLYMOUTH MEETING, PA [February 17, 2021] -- The National Comprehensive Cancer Network® (NCCN®) today published its first-ever treatment guidelines for children with a solid tumor cancer type in the ...

Invivyd, Inc. has announced that its investigational monoclonal antibody, PEMGARDA® (pemivibart), has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for ...

The National Comprehensive Cancer Network expands interactive library of evidence-based, expert consensus-driven cancer care guidance to now cover treatment for more than a dozen cancer types, along ...